Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics, Inc. filed a current report to note that it has posted a new corporate presentation on its website. The presentation, dated January 29, 2026 and filed as Exhibit 99.1, will be used by company representatives in various investor meetings.
The filing does not introduce new financial results or major transactions, but formally makes the investor presentation part of the public record by incorporating it by reference into the report.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported option exercises and related share sales in Palvella Therapeutics, Inc. common stock. On January 21, 2026, she exercised stock options for 2,154 shares at $7.14 and 2,148 shares at $9.08 per share. The resulting common shares were then sold in two transactions totaling 4,302 shares, with 553 shares sold at $95.49 and 3,749 shares sold at $97.94, leaving no directly held common stock reported after these sales. Following the option exercises, she continued to hold 19,397 and 19,332 stock options, each fully vested. The filing states that all transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025 during an open trading window and approved under the company’s insider trading policy.
Palvella Therapeutics insider plans another Rule 144 stock sale. A person filing through Piper Sandler & Co. intends to sell 4,302 shares of Palvella Therapeutics common stock on or about 01/21/2026 on the Nasdaq market, with an aggregate market value of 421,639.02 reported for this planned sale. The shares are being acquired the same day via a stock option exercise from the issuer, paid in cash, and then sold.
The filing also notes that the same seller, identified as Kathleen Goin c/o Palvella Therapeutics, previously sold 4,302 shares of common stock on 11/19/2025 for gross proceeds of 370,750.23 and another 4,302 shares on 12/17/2025 for gross proceeds of 415,022.54. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about Palvella Therapeutics’ current or prospective operations.
Palvella Therapeutics, Inc. filed a current report to note that on January 12, 2026 it posted a new corporate presentation on its website. Company representatives plan to use this presentation in meetings with investors from time to time. The presentation is also included as Exhibit 99.1 to the report, making the same information available through the SEC’s system.
Palvella Therapeutics, Inc. reported a key clinical update for its dermatology program. On December 15, 2025, the company scheduled an investor conference call to present topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations, a vascular skin condition. The call is accompanied by an online slide presentation, provided as Exhibit 99.1.
Palvella also issued a press release, filed as Exhibit 99.2, announcing positive topline results from this ongoing Phase 2 study. Together, the call, slides, and press release highlight progress in the clinical development of QTORIN for this indication, giving investors more detail on how the program is advancing.
Palvella Therapeutics (PVLA) reported insider transactions by its Chief Operating Officer on a Form 4. On 11/19/2025, the officer exercised stock options to acquire 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share. The same day, the officer sold 1,500 shares at a weighted average price of $85.7183 and 2,802 shares at a weighted average price of $86.5053, leaving 0 shares of common stock directly owned after these transactions.
The filing shows remaining fully vested stock options covering 2,154 shares expiring on 10/29/2029 and 2,148 shares expiring on 10/14/2030, with post‑transaction option holdings of 23,705 and 23,628 options in those grants. All transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025.
Palvella Therapeutics (PVLA) reported third‑quarter 2025 results highlighting increased investment in late‑stage programs and a larger loss. Cash and cash equivalents were $63.6 million at September 30, 2025, down from $83.6 million at year‑end. Q3 operating expenses rose to $10.2 million, driven by research and development of QTORIN rapamycin and higher general and administrative costs. The company recorded a net loss of $11.3 million for Q3 2025 and $29.0 million year‑to‑date.
Palvella’s royalty agreement liability increased to $16.0 million, with non‑cash interest expense of $1.5 million in Q3. Net cash used in operating activities was $20.1 million for the nine months. Management states existing cash is sufficient to support operations for at least one year from the financial statement issuance date. Clinical progress continued: the Phase 3 SELVA trial completed enrollment with 51 patients, and the Phase 2 TOIVA trial completed enrollment with 16 patients. The company recognized $0.4 million of government grant income year‑to‑date related to SELVA and received $0.5 million in May and $0.6 million in October 2025. Shares outstanding were 11,836,490 as of November 7, 2025.
Palvella Therapeutics, Inc. furnished an update that it will announce its financial results for the quarter ended September 30, 2025 and hold an earnings call on November 11, 2025. The company attached its press release as Exhibit 99.1 and an earnings call slide presentation as Exhibit 99.2.
The materials are furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes under the Exchange Act, except as expressly incorporated by reference. Palvella’s common stock trades on the Nasdaq Capital Market under the symbol PVLA.
Palvella Therapeutics (PVLA) announced a new product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis (DSAP). The company is hosting an investor call on November 5, 2025 at 8:30 a.m. Eastern Time, with materials available via a webcast link.
An investor presentation was furnished as Exhibit 99.1 and a press release as Exhibit 99.2. The information was furnished under Item 7.01 and is not deemed filed under the Exchange Act.
Palvella Therapeutics disclosed on September 24, 2025 that it is expanding the development program for QTORIN™ 3.9% rapamycin anhydrous gel into Clinically Significant Angiokeratomas. The filing notes a press release describing this expansion has been furnished as Exhibit 99.1 and is being made under Regulation FD disclosure standards.
The notice is procedural in form: it confirms the program expansion but does not provide clinical data, trial design, timelines, or cost information. The filing is signed by the company’s Chief Financial Officer, indicating formal corporate disclosure rather than new regulatory approvals or completed clinical results.
Palvella Therapeutics disclosed on September 24, 2025 that it is expanding the development program for QTORIN™ 3.9% rapamycin anhydrous gel into Clinically Significant Angiokeratomas. The filing notes a press release describing this expansion has been furnished as Exhibit 99.1 and is being made under Regulation FD disclosure standards.
The notice is procedural in form: it confirms the program expansion but does not provide clinical data, trial design, timelines, or cost information. The filing is signed by the company’s Chief Financial Officer, indicating formal corporate disclosure rather than new regulatory approvals or completed clinical results.